Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
02 March 2012Website:
http://www.volition.comNext earnings report:
26 March 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 42 min agoDividend
Analysts recommendations
Institutional Ownership
VNRX Latest News
VolitionRx Limited (NYSE:VNRX ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Tom Butera - CEO, Volition Veterinary Diagnostic Development Andrew Retter - Chief Medical Officer Terig Hughes - CFO Cameron Reynolds - President & CEO Conference Call Participants Jason Kolbert - D. Boral Capital Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Investment Research Bruce Jackson - The Benchmark Company Operator Good day, ladies and gentlemen.
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
HENDERSON, Nev. , Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management.
Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev. , Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its common stock (or common stock equivalents in lieu thereof) and milestone-linked warrants, composed of series A warrants to purchase up to 12,727,273 shares of common stock and series B warrants to purchase up to 12,727,273 shares of common stock, at an offering price of $0.55 per share (or common stock equivalent in lieu thereof) and accompanying warrants.
HENDERSON, Nev. , July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio.
VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.
VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfolio. The multi-national epigenetics company said the funds will also be used to advance the clinical and regulatory program for Nu.Q NETs, which it believes will aid the early diagnosis of diseases such as sepsis, as it works with leading clinicians and researchers to help facilitate the effective introduction of the diagnostic solution into clinical practice.
VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Tim Moore - EF Operator Good morning, ladies and gentlemen. Thank you for standing by.
- 1(current)
What type of business is VolitionRx Limited?
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
What sector is VolitionRx Limited in?
VolitionRx Limited is in the Healthcare sector
What industry is VolitionRx Limited in?
VolitionRx Limited is in the Diagnostics & Research industry
What country is VolitionRx Limited from?
VolitionRx Limited is headquartered in United States
When did VolitionRx Limited go public?
VolitionRx Limited initial public offering (IPO) was on 02 March 2012
What is VolitionRx Limited website?
https://www.volition.com
Is VolitionRx Limited in the S&P 500?
No, VolitionRx Limited is not included in the S&P 500 index
Is VolitionRx Limited in the NASDAQ 100?
No, VolitionRx Limited is not included in the NASDAQ 100 index
Is VolitionRx Limited in the Dow Jones?
No, VolitionRx Limited is not included in the Dow Jones index
When was VolitionRx Limited the previous earnings report?
No data
When does VolitionRx Limited earnings report?
The next expected earnings date for VolitionRx Limited is 26 March 2025